These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 22890797)
81. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Vaage J; Donovan D; Mayhew E; Abra R; Huang A Cancer; 1993 Dec; 72(12):3671-5. PubMed ID: 8252484 [TBL] [Abstract][Full Text] [Related]
82. Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia? Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Neumeister V; Wirth MP; Siegert G Inflammation; 2012 Jun; 35(3):1113-8. PubMed ID: 22189868 [TBL] [Abstract][Full Text] [Related]
83. A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo. Shi C; Gao F; Gao X; Liu Y Biomed Pharmacother; 2015 Feb; 69():191-200. PubMed ID: 25661357 [TBL] [Abstract][Full Text] [Related]
85. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682 [TBL] [Abstract][Full Text] [Related]
86. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs. Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779 [TBL] [Abstract][Full Text] [Related]
87. Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A Tagami T; Ando Y; Ozeki T Int J Pharm; 2017 Jan; 517(1-2):35-41. PubMed ID: 27865984 [TBL] [Abstract][Full Text] [Related]
88. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260 [TBL] [Abstract][Full Text] [Related]
89. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567 [TBL] [Abstract][Full Text] [Related]
90. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672 [TBL] [Abstract][Full Text] [Related]
91. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258 [TBL] [Abstract][Full Text] [Related]
92. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. Dagar S; Krishnadas A; Rubinstein I; Blend MJ; Onyüksel H J Control Release; 2003 Aug; 91(1-2):123-33. PubMed ID: 12932644 [TBL] [Abstract][Full Text] [Related]
93. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Horowitz AT; Barenholz Y; Gabizon AA Biochim Biophys Acta; 1992 Aug; 1109(2):203-9. PubMed ID: 1520697 [TBL] [Abstract][Full Text] [Related]
94. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo . Kubota T; Hisatake J; Hisatake Y; Said JW; Chen SS; Holden S; Taguchi H; Koeffler HP Prostate; 2000 Feb; 42(3):163-71. PubMed ID: 10639186 [TBL] [Abstract][Full Text] [Related]
95. Novel insights of secretory phospholipase a(2) action in cardiology. Fujioka D; Kugiyama K Trends Cardiovasc Med; 2009 Apr; 19(3):100-3. PubMed ID: 19679267 [TBL] [Abstract][Full Text] [Related]
96. Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection. Thamphiwatana S; Gao W; Pornpattananangkul D; Zhang Q; Fu V; Li J; Li J; Obonyo M; Zhang L J Mater Chem B; 2014 Dec; 2(46):8201-8207. PubMed ID: 25544886 [TBL] [Abstract][Full Text] [Related]
97. Facial Amphiphile-Modified Lipids Highly Sensitize Liposomes toward Secretory Phospholipase A Liu Y; Yao X; Wen C; Li D; Zhang J; Xi B; Cummings BS; Zhu G Mol Pharm; 2024 Nov; 21(11):5469-5481. PubMed ID: 39397289 [TBL] [Abstract][Full Text] [Related]
99. Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro. Tang H; Zhang Z; Zhu M; Xie Y; Lv Z; Liu R; Shen Y; Pei J Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986849 [TBL] [Abstract][Full Text] [Related]
100. Enzyme-responsive liposomes for controlled drug release. Wei Y; Lv J; Zhu S; Wang S; Su J; Xu C Drug Discov Today; 2024 Jul; 29(7):104014. PubMed ID: 38705509 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]